Contact Us
Drug Search Results
More Filters [+]

Amsilarotene

Alternative Names: amsilarotene, tac-101, tac101, tac 101
Latest Update: 2024-10-30
Latest Update Note: News Article

Product Description

Amsilarotene (TAC-101) is a retinobenzoic acid (RAR) derivative with high affinity to the RAR-alpha receptor. It is a Retinoic acid receptor alpha antagonist. Amsilarotene is an orally absorbed synthetic retinoid. (Sourced from: https://drugs.ncats.io/drug/Q1418F39MH)

Mechanisms of Action: RARa Binder

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Taiho
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Amsilarotene

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatocellular Carcinoma|Liver Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2007-007629-32

P2

Terminated

Hepatocellular Carcinoma

2012-04-19

TAC101-202

P2

Terminated

Hepatocellular Carcinoma

2010-05-10

TAC101-203

P2

Terminated

Hepatocellular Carcinoma

2009-12-22

TAC101-204

P2

Withdrawn

Hepatocellular Carcinoma

2008-12-01

Recent News Events

Date

Type

Title

10/30/2024

News Article

 Triumvira Immunologics to Present New Clinical Data from Ongoing Claudin 18.2 Phase 1 Study in Late-Breaking Oral Presentation at 39th SITC Annual Meeting

05/05/2024

PubMed

 Vitamins in Gynecologic Malignancies.

02/05/2024

News Article

 Triumvira Immunologics Announces First Patient Dosed in Phase I/II Cell Therapy Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors

08/01/2021

PubMed

 Differential Effect of a Continental Breakfast on Tacrolimus Formulations With Different Release Characteristics.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions